参考文献/References:
[1] Deroo BJ,Korach KS. Estrogen receptors and human disease[J].J Clin Invest,2006,(3):561-570.
[2] Leung YK,Mak P,Hassan S,et al. Estrogen receptor(ER)-beta isoforms:a key to understanding ER-beta signaling[J].Proc Natl Acad Sci U S A,2006,103(35):13162-13167.
[3] Heldring N,Pike A,Andersson S,et al. Estrogen receptors:how do they signal and what are their targets[J].Physiol Rev,2007,87(3):905-931.
[4] Li X,Huang J,Yi P,et al. Single-chain estrogen receptors(ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways[J].Mol Cell Biol,2004,24(17):7681-7694.
[5] Aranda A,Pascual A. Nuclear hormone receptors and gene expression[J].Physiol Rev,2001,81(3):1269-1304.
[6] Glass CK,Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors[J].Genes Dev,2000,14(2):121-141.
[7] Heery DM,Kalkhoven E,Hoare S,et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors[J].Nature,1997,387(6634):733-736.
[8] Zhang H,Thomsen JS,Johansson L,et al. DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors[J].J Biol Chem,2000,275(51):39855-39859.
[9] Ogryzko VV,Schiltz RL Russanova V,et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases[J].Cell,1996,87(5):953-959.
[10] Koshiishi N,Chong JM,Fukasawa T,et al. p300 gene alterations in intestinal and diffuse types of gastric carcinoma[J].Gastric Cancer,2004,7(2):85-90.
[11] Ding XF,Anderson CM,Ma H,et al. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1(GRIP1) and steroid receptor coactivator 1(SRC-1):multiple motifs with different binding specificities[J].Mol Endocrinol,1998,12(2):302-313.
[12] Voegel JJ,Heine MJ,Tini M,et al. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and-independent pathways[J].EMBO J,1998,12(2):507-519.
[13] Kurebayashi J,Otsuki T,Kunisue H,et al. Expression levels of estrogen receptor-alpha,estrogen receptor-beta,coactivators,and corepressors in breast cancer[J].Clin Cancer Res,2000,6(2):512-518.
[14] Blanco JC,Minucci S,Lu J,et al. The histone acetylase PCAF is a nuclear receptor coactivator[J].Genes Dev,1998,12(11):1638-1651.
[15] Giannini R,Cavallini A. Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma[J].Anticancer Res,2005,25(6B):4287-4292.
[16] Yuan CX,Ito M,Fondell JD,et al. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion[J].Proc Natl Acad Sci U S A,1998,95(14):7939-7944.
[17] Kitagawa H,Fujiki R,Yoshimura K,et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome[J].Cell,2003,113(7):905-917.
[18] Li H,Chen JD. The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation[J].J Biol Chem,1998,273(10):5948-5954.
[19] Anzick SL,Kononen J,Walker RL,et al. AIB1,a steroid receptor coactivator amplified in breast and ovarian cancer[J].Science,1997,277(5328):965-968.
[20] Li D,Desai-Yajnik V,Lo E,et al. NRIF3 is a novel coactivator mediating functional specificity of nuclear hormone receptors[J].Mol Cell Biol,1999,19(10):7191-7202.
[21] Talukder AH,Gururaj A,Mishra SK,et al. Metastasis-associated protein 1 interacts with NRIF3,an estrogen-inducible nuclear receptor coregulator[J].Mol Cell Biol,2004,24(15):6581-6591.
[22] Kim HJ,Yi JY,Sung HS,et al. Activating signal cointegrator 1,a novel transcription coactivator of nuclear receptors,and its cytosolic localization under conditions of serum deprivation[J].Mol Cell Biol,1999,19(9):6323-6332.
[23] Luciano RL,Wilson AC. N-terminal transcriptional activation domain of LZIP comprises two LxxLL motifs and the host cell factor-1 binding motif[J].Proc Natl Acad Sci U S A,2000,97(20):10757-10762.
[24] Vega RB,Huss JM,Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes[J].Mol Cell Biol,2000,20(5):1868-1876.
[25] Puigserver P,Spiegelman BM,et al. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha(PGC-1 alpha):transcriptional coactivator and metabolic regulator[J].Endocr Rev,2003,24(1):78-90.
[26] Zhu Y,Kan L,Qi C. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP)as a coactivator for PPAR[J].J Biol Chem,2000,275(18):13510-13516.
[27] Sj?blom T,Jones S,Wood LD,et al. The consensus coding sequences of human breast and colorectal cancers[J].Science,2006,314(5797):268-274.
[28] Ko L,Cardona GR,Chin WW. Thyroid hormone receptor-binding protein,an LXXLL motif-containing protein,functions as a general coactivator[J].Proe Natl Acad Sci U S A,2000,97(11):6212-6217.
[29] Sauvé F,McBroom LD,Gallant J,et al. CIA,a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant[J].Mol Cell Biol,2001,21(1):343-353.
[30] Zhou D,Chen S. PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif[J].Nucleic Acids Res,2001,29(19):3939-3948.
[31] Gaughan L,Brady ME,Cook S,et al. Tip60 is a co-activator specific for class Ⅰ nuclear hormone receptors[J].J Biol Chem,2001,276(50):46841-46848.
[32] Kressler D,Schreiber SN,Knutti D,et al. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha[J].J Biol Chem,2002,277(16):13918-13925.
[33] Meirhaeghe A,Crowley V,Lenaghan C,et al. Characterization of the human,mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta)gene in vitro and in vivo[J].Biochem J,2003,373(Pt 1):155-165.
[34] Wang Q,Sharma D,Ren Y,et al. A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression[J].J Biol Chem,2002,277(45):42852-42858.
[35] Clark J,Edwards S,John M,et al. Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones[J].Genes Chromosomes & Cancer,2002,34(1):104-114.
[36] Barletta F,Wong CW,Mcnally C,et al. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc[J].Mol Endocrinol,2004,18(5):1096-1108.
[37] Vadlamudi RK,Manavathi B,Balasenthil S. Functional implications of altered subcellular localization of PELPI in breast cancer cells[J].Cancer Res,2005,65(17):7724-7732.
[38] Mo R,Rao SM,Zhu YJ. Identification of the MLL2 complex as a coactivator for estrogen receptor alpha[J].J Biol Chem,2006,281(23):15714-15720.
[39] Choudhary C,Kumar C,Gnad F,et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions[J].Science,2009,325(5942):834-840.
[40] Chen M,Ni J,Chang HC,et al. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells[J].Carcinogenesis,2009,30(5):841-850.
[41] Khurana S,Chakraborty S,Cheng XW,et al. The actin-binding protein,actinin alpha 4(ACTN4),is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells[J].J Biol Chem,2011,286(3):1850-1859.
[42] Heery DM,Hoare S,Hussain S,et al. Core LXXLL motif sequences in CREB-binding protein,SRC1,and RIP140 define affinity and selectivity for steroid and retinoid receptors[J].J Biol Chem,2001,276(9):6695-6702.
[43] Teo AK,Oh HK,Ali RB,et al. The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage[J].Mol Cell Biol,2001,21(20):7105-7114.
[44] Fernandes I,Bastien Y,Wai T,et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and-independent mechanisms[J].Mol Cell,2003,11(1):139-150.
[45] Martini PG,Katzenellenbogen BS. Modulation of estrogen receptor activity by selective coregulators[J].J Steroid Biochem Mol Biol,2003,85(2-5):117-122.
[46] Meng Q,Zhao Z,Yan M,et al. ERR-10:a new repressor in transcriptional signaling activation of estrogen receptor-alpha[J].FEBS Lett,2004,576(1-2):190-200.
[47] Song KH,Li T,Chiang JY. A Prospero-related homeodomain protein is a novel co-regulator of hepatocyte nuclear factor 4alpha that regulates the cholesterol 7alpha-hydroxylase gene[J].J Biol Chem,2006,281(15):10081-10088.
[48] Rossi M,Colecchia D,Iavarone C,et al. Extracellular signal-regulated kinase 8(ERK8) controls estrogen-related receptor α (ERRα) cellular localization and inhibits its transcriptional activity[J].J Biol Chem,2011,286(10):8507-8522.
[49] Zhang J,Kalkum M,Yamamura S,et al. E protein silencing by the leukemogenic AML1-ETO fusion protein[J].Science,2004,305(5688):1286-1289.
[50] Razeto A,Ramakrishnan V,Litterst CM,et al. Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain[J].J Mol Biol,2004,336(2):319-329.
[51] Benecke A,Gaudon C,Gamier J M,et al. ADA3-containing complexes associate with estrogen receptor alpha[J].Nucleic Acids Res,2002,30(11):2508-2514.
[52] Bourguet W,Germain P,Gronemeyer H. Nuclear receptor ligandbinding domains:three-dimensional structures,molecular interactions and pharmacological implications[J].Trends Pharmacol Sci,2000,21(10):381-388.
[53] Moras D,Gronemeyer H. The nuclear receptor ligand-binding domain:structure and function[J].Curr Opin Cell Biol,1998,10(3):384-391.
[54] Feng W,Ribeiro RC,Wagner RL,et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors[J].Science,1998,280(5370):1747-1749.
[55] Baniahmad A,Leng X,Burris TP,et al. The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor (s)necessary for transcriptional silencing[J].Mol Cell Biol,1995,15(1):76-86.
[56] Bourguet W,Ruff M,Chambon P,et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha[J].Nature,1995,375(6530):377-382.
[57] Shiau AK,Barstad D,Loria PM,et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen[J].Cell,1998,95(7):927-937.
[58] Brzozowski AM,Pike AC,Dauter Z,et al. Mol basis of agonism and antagonism in the oestrogen receptor[J].Nature,1997,389(6652):753-758.
[59] Darimont BD,Wagner RL,Apriletti JW,et al. Structure and specificity of nuclear receptor-coactivator interactions[J].Genes Dev,1998,12(21):3343-3356.
[60] Nolte RT,Wisely GB,Westin S,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptorgamma[J].Nature,1998,395(6698):137-143.
[61] W?rnmark A,Treuter E,Gustafsson JA,et al. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha[J].J Biol Chem,2002,277(24):21862-21868.
[62] Klein F,Atkinson RA,Potier N,et al. Biochemical and NMR mapping of the interface between CREB-binding protein and ligand binding domains of nuclear receptor-Beyond the LXXLL motif[J].J Biol Chem,2005,280(7):5682-5692.
[63] Hur E,Pfaff SJ,Payne ES,et al. Recognition and accommodation at the androgen receptor coactivator binding interface[J].PLoS Biol,2004,2(9):E274.
[64] Mcinerney EM,Rose DW,Flynn SE,et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation[J].Genes Dev,1998,12(21):3357-3368.
[65] Gee AC,Carlson KE,Martini PG,et al. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor[J].Mol Endocrinol,1999,13(11):1912-1923.
[66] Rha GB,Wu G,Shoelson SE,et al. Multiple binding modes between HNF4 alpha and the LXXLL motifs of PGC-1alpha lead to full activation[J].J Biol Chem,2009,284(50):35165-35176.
[67] Varlakhanova N,Snyder C,Jose S,et al. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the eorepressor N terminus and the receptor DNA binding domain[J].Mol Cell Biol,2010,30(6):1434-1445.
[68] Heldring N,Pawson T,Mcdonnell D,et al. Structural insights into corepressor recognition by antagonist-bound estrogen receptors[J].J Biol Chem,2007,282(14):10449-10455.
[69] Galande AK,Bramlett KS,Trent JO,et al. Potent inhibitors of LXXLL-based protein-protein interactions[J].Chem Bio Chem,2005,6(11):1991-1998.
[70] Chang Cy,Norris JD,Gr?n H. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries:discovery of peptide antagonists of estrogen receptors alpha and beta[J].Mol Cell Biol,1999,19(12):8226-8239.
[71] Rodriguez AL,Tamrazi A,Collins ML. Design,synthesis,and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding[J].J of Medicinal Chemistry,2004,(3):600-611.
[72] Parent AA,Gunther JR,Katzenellenbogen JA. Blocking estrogen signaling after the hormone:pyrimidine-core inhibitors of estrogen receptor-coactivator binding[J].J Med Cbem,2008,(20):6512-6530.
[73] Gunther JR,Moore TW,Collins ML,et al. Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interaction[J].ACS Chem Biol,2008,3(5):282-286.
[74] Lafrate AL,Gunther JR,Carlson KE,et al. Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor[J].Bioorg Med Chem,2008,16(23):10075-10084.
[75] Phan T,Nguyen HD,G?ksel H. Phage display selection of miniprotein hinders of the estrogen receptor[J].Chem Commun (Camb),2010,46(43):8207-8209.
[76] Shao D,Benrodin TJ,Manas E,et al. Identification of novel estrogen receptor alpha antagonists[J].J Steroid Biochem Mol Biol,2004,88(4-5):351-360.
[77] Zhou HB,Collins ML,Gunther JR,et al. Bicyclo[2.2.2] octanes:close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators[J].Bioorg Med Chem Lett,2007,17(15):4118-4122.
[78] Hruby VJ,Li G,Haskell-Luevano C,et al. Design of peptides,proteins,and peptidomimetics in chi space[J].Biopolymers,1997,43(3):219-266.
[79] Carraz M,Zwart W,Phan T,et al. Perturbation of estrogen receptor alpha localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors[J].Chem Biol,2009,16(7):702-711.
[80] Moellering RE,Cornejo M,Davis TN,et al. Direct inhibition of the NOTCH transcription factor complex[J].Nature,2009,462(7270):182-188.
[81] Hu XD,Meng QH,Xu JY,et al. BTG2 is an LXXLL-dependent corepressor for androgen receptor transcriptional activity[J].Biochem Biophys Res Commun,2011,404(4):903-909.
[82] Sun KK,Zhong N,Yang Y,et al. Enhanced radiosensitivity of NSCLC cells by transducer of erbB2.1(TOB1)through modulation of the MAPK/ERK pathway[J].Oncol Rep,2013,29(6):2385-2391.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[5]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[6]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[7]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[8]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[9]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[10]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[11]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[12]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[13]孟召伟,董峰,谭建.乳腺癌的雌激素受体显像[J].国际放射医学核医学杂志,2007,31(3):157.
MENG Zhao-wei,DONG Feng,TAN Jian.Estrogen receptor imaging in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):157.